PMID- 35994200
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20231106
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 82
IP  - 12
DP  - 2022 Aug
TI  - Ozanimod: A Review in Ulcerative Colitis.
PG  - 1303-1313
LID - 10.1007/s40265-022-01762-8 [doi]
AB  - Ozanimod (Zeposia((R))) is the first sphingosine-1-phosphate receptor (S1PR) 
      modulator to be approved for the treatment of adults with moderately to severely 
      active ulcerative colitis in the USA, and in adults with moderately to severely 
      active ulcerative colitis who have had an inadequate or lost response to, or were 
      intolerant of, either conventional therapy or a biologic in the EU. An oral 
      agent, ozanimod is administered once daily as induction and maintenance therapy. 
      In the randomized, double-blind, multinational phase 2 Touchstone and phase 3 
      True North clinical trials, ozanimod was effective in inducing clinical remission 
      and maintaining remission relative to placebo in adults with moderately to 
      severely active ulcerative colitis. Ozanimod was generally well tolerated in 
      these studies, with manageable or transient adverse events (AEs). Current data 
      from the Touchstone and True North open-label extensions are consistent with the 
      primary studies with respect to therapeutic efficacy and tolerability, with no 
      new safety signals observed. Although further data will be beneficial, ozanimod 
      expands the treatment options for adults with moderately to severely active 
      ulcerative colitis.
CI  - (c) 2022. Springer Nature.
FAU - Paik, Julia
AU  - Paik J
AD  - Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. 
      demail@springer.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220822
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Biological Products)
RN  - 0 (Indans)
RN  - 0 (Oxadiazoles)
RN  - 0 (Sphingosine-1-Phosphate Receptors)
RN  - Z80293URPV (ozanimod)
SB  - IM
EIN - Drugs. 2022 Sep 1;:. PMID: 36050602
MH  - Administration, Oral
MH  - Adult
MH  - *Biological Products/therapeutic use
MH  - *Colitis, Ulcerative/drug therapy
MH  - Humans
MH  - Indans
MH  - Oxadiazoles
MH  - Randomized Controlled Trials as Topic
MH  - Remission Induction
MH  - Sphingosine-1-Phosphate Receptors
PMC - PMC9499884
OAB - Ulcerative colitis is a chronic inflammatory bowel disease involving a 
      dysregulated immune response in the intestinal mucosa. Conventional therapy 
      options for moderate to severe ulcerative colitis are initially effective, but 
      associated with increased risk of adverse events, resistance to treatment, or 
      loss of response over time. Consequently, small molecule drugs have become of 
      interest as alternative treatment options. Ozanimod (Zeposia((R))) is an oral drug 
      that targets and modulates the activity of sphingosine-1-phosphate receptors to 
      reduce the movement of lymphocytes from the lymph nodes to sites of inflammation. 
      Compared with placebo, ozanimod significantly improved rates of clinical 
      remission and was generally well tolerated in adults with moderately to severely 
      active ulcerative colitis. Findings from open-label extension studies suggest 
      that ozanimod remains efficacious and generally well tolerated with long-term 
      use. Although further data will be beneficial, ozanimod expands the treatment 
      options for adults with moderately to severely active ulcerative colitis.
OABL- eng
COIS- Julia Paik is a salaried employee of Adis International Ltd/Springer Nature, and 
      declares no relevant conflicts of interest. All authors contributed to the review 
      and are responsible for the article content.
EDAT- 2022/08/23 06:00
MHDA- 2022/09/28 06:00
PMCR- 2022/08/22
CRDT- 2022/08/22 11:26
PHST- 2022/08/02 00:00 [accepted]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/08/22 11:26 [entrez]
PHST- 2022/08/22 00:00 [pmc-release]
AID - 10.1007/s40265-022-01762-8 [pii]
AID - 1762 [pii]
AID - 10.1007/s40265-022-01762-8 [doi]
PST - ppublish
SO  - Drugs. 2022 Aug;82(12):1303-1313. doi: 10.1007/s40265-022-01762-8. Epub 2022 Aug 
      22.